To start, comanagers Wendy Lam and Akiva Felt, who hold a doctorate in biology and a master's in biotechnology, respectively, dig into clinical trial data to evaluate each drug's efficacy.

Franklin Biotechnology Discovery A made its debut in September of 1997, and since then, FBDIX has accumulated about $729 million in assets, per the most up-to-date date available.

We still have much to learn about how our bodies and brains work. These innovators are investigating the nature of disease and exploring how technology can help us live longer, healthier lives. He ...

A new clinical trial of a ground-breaking phage-based molecular diagnostic, has been agreed. The trial is aimed at evaluating the performance of the phage assay as a first-line blood-based diagnostic ...

The S&P 500 added 0.8% on Thursday, Sept. 12, 2024, extending its winning streak to four days as the latest PPI data showed a ...

Biotech Fluidics announce the foundation of Ventri Labs AB (VentriLabs) – a new subsidiary set-up to leverage the disruptive benefits of its patented gravity liquid pump technology for handling of ...

More needs to be done to tap the potential of drug discovery programs in mid-tier biotech companies for innovative ... ranging from improved public image and workforce motivation to a potential ...

Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024" report has been added to ResearchAndMarkets.com's offering.

To start, comanagers Wendy Lam and Akiva Felt, who hold a doctorate in biology and a master's in biotechnology, respectively, dig into clinical trial data to evaluate each drug's efficacy.

Sector - Health fund seekers should consider taking a look at Franklin Biotechnology Discovery A (FBDIX). FBDIX holds a Zacks Mutual Fund Rank of 2 (Buy), which is based on various forecasting ...